Standout Papers

The diagnosis and management of nonalcoholi... 2006 2026 2012 2019 4.9k
  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2017)
    Naga Chalasani, Zobair M. Younossi et al. Hepatology
  2. Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis Among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study (2010)
    Christopher D. Williams, Joel Z. Stengel et al. Gastroenterology
  3. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis (2006)
    Renata Belfort, Stephen A. Harrison et al. New England Journal of Medicine
  4. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis (2020)
    Philip N. Newsome, Kristine Buchholtz et al. New England Journal of Medicine
  5. Nonalcoholic Fatty Liver Disease and Hepatocellular Carcinoma: A Weighty Connection (2010)
    Stephen A. Harrison et al. Hepatology
  6. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease (2008)
    Stephen A. Harrison, D.R. Oliver et al. Gut
  7. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis (2003)
    Stephen A. Harrison, Paul H. Hayashi et al. The American Journal of Gastroenterology
  8. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2019)
    Stephen A. Harrison, Mustafa R. Bashir et al. The Lancet
  9. Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial (2018)
    Arun J. Sanyal, Edgar D. Charles et al. The Lancet
  10. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2018)
    Stephen A. Harrison, Mary E. Rinella et al. The Lancet
  11. Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease (2021)
    Fasiha Kanwal, Jay H. Shubrook et al. Gastroenterology
  12. Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study (2020)
    Vlad Ratziu, Arun J. Sanyal et al. Hepatology
  13. From NAFLD to MAFLD: Implications of a Premature Change in Terminology (2020)
    Zobair M. Younossi, Mary E. Rinella et al. Hepatology
  14. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease (2018)
    Rohit Loomba, Zeid Kayali et al. Gastroenterology
  15. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials (2019)
    Arun J. Sanyal, Stephen A. Harrison et al. Hepatology
  16. Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials (2020)
    Beth A. Davison, Stephen A. Harrison et al. Journal of Hepatology
  17. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH (2023)
    Rohit Loomba, Arun J. Sanyal et al. New England Journal of Medicine
  18. Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial (2021)
    Stephen A. Harrison, Peter Ruane et al. Nature Medicine
  19. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis (2020)
    Stephen A. Harrison, Guy Neff et al. Gastroenterology
  20. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial (2023)
    Stephen A. Harrison, Rebecca Taub et al. Nature Medicine
  21. Challenges and opportunities in NASH drug development (2023)
    Stephen A. Harrison, Alina M. Allen et al. Nature Medicine
  22. Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort (2021)
    Stephen A. Harrison, Samer Gawrieh et al. Journal of Hepatology
  23. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial (2021)
    Rohit Loomba, Rizwana Mohseni et al. Gastroenterology
  24. NAFLD‐related hepatocellular carcinoma: The growing challenge (2022)
    Pir Ahmad Shah, Rashmee Patil et al. Hepatology
  25. Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial (2023)
    Stephen A. Harrison, Juan P. Frías et al. ˜The œLancet. Gastroenterology & hepatology
  26. Current therapies and new developments in NASH (2022)
    Jean‐François Dufour, Quentin M. Anstee et al. Gut
  27. Clinical Trial Landscape in NASH (2023)
    Stephen A. Harrison, Rohit Loomba et al. Clinical Gastroenterology and Hepatology
  28. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond (2024)
    Stephen A. Harrison, Tim Rolph et al. Journal of Hepatology
  29. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study (2024)
    Stephen A. Harrison, Sarah Browne et al. Journal of Hepatology
  30. The Emerging Role of Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (2024)
    Pir Ahmad Shah, Robert H. Eckel et al. Clinical Gastroenterology and Hepatology
  31. Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2b trial (2024)
    Rohit Loomba, Pierre Bédossa et al. ˜The œLancet. Gastroenterology & hepatology

Immediate Impact

5 by Nobel laureates 7 from Science/Nature 351 standout
Sub-graph 1 of 16

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
201 intermediate papers

Works of Stephen A. Harrison being referenced

FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond
2024 Standout
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
2023 Standout
and 102 more

Author Peers

Author Last Decade Papers Cites
Stephen A. Harrison 24793 11080 11597 387 30.7k
Elisabetta Bugianesi 26731 10190 12431 282 31.7k
Arthur J. McCullough 27432 11779 11652 292 34.4k
Brent A. Neuschwander‐Tetri 24212 9883 10995 186 29.7k
Quentin M. Anstee 18861 8645 7626 247 22.8k
Geoffrey C. Farrell 19440 9801 6780 213 25.5k
Linda Henry 19351 9860 7057 272 23.6k
Ariel E. Feldstein 16818 6164 6567 218 26.3k
Christopher D. Byrne 16202 4994 10048 494 25.7k
Leon A. Adams 18336 8886 7643 198 22.2k
Giovanni Targher 27937 8537 16995 548 42.4k

All Works

Loading papers...

Rankless by CCL
2026